MoonLake Net Income Per Share vs Free Cash Flow Yield Analysis

MLTX Stock

USD 54.43 0.19 0.35%

MoonLake Immunotherapeuti financial indicator trend analysis is infinitely more than just investigating MoonLake Immunotherapeuti recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether MoonLake Immunotherapeuti is a good investment. Please check the relationship between MoonLake Immunotherapeuti Net Income Per Share and its Free Cash Flow Yield accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MoonLake Immunotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Net Income Per Share vs Free Cash Flow Yield

Net Income Per Share vs Free Cash Flow Yield Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of MoonLake Immunotherapeuti Net Income Per Share account and Free Cash Flow Yield. At this time, the significance of the direction appears to have totally related.

The correlation between MoonLake Immunotherapeuti's Net Income Per Share and Free Cash Flow Yield is 0.99. Overlapping area represents the amount of variation of Net Income Per Share that can explain the historical movement of Free Cash Flow Yield in the same time period over historical financial statements of MoonLake Immunotherapeutics, assuming nothing else is changed. The correlation between historical values of MoonLake Immunotherapeuti's Net Income Per Share and Free Cash Flow Yield is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income Per Share of MoonLake Immunotherapeutics are associated (or correlated) with its Free Cash Flow Yield. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Free Cash Flow Yield has no effect on the direction of Net Income Per Share i.e., MoonLake Immunotherapeuti's Net Income Per Share and Free Cash Flow Yield go up and down completely randomly.

Correlation Coefficient

0.99

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Net Income Per Share

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Most indicators from MoonLake Immunotherapeuti's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into MoonLake Immunotherapeuti current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in MoonLake Immunotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

Enterprise Value is likely to rise to about 2.6 B in 2024, whereas Selling General Administrative is likely to drop slightly above 18.3 M in 2024.

	2021	2022	2023	2024 (projected)
Other Operating Expenses	4.6M	65.1M	54.1M	34.1M
Depreciation And Amortization	5.0K	12.4K	13.2K	12.5K

Other Operating Expenses Depreciation And Amortization

MoonLake Immunotherapeuti fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Cash	Non Current Assets Total	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Warrants	Accounts Payable	Non Currrent Assets Other	Net Receivables	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.06	0.57	0.28	1.0	-0.98	-0.75	0.98	-0.46	0.97	0.79	-0.14	0.36	0.33	0.97	-0.17	-0.51	-0.94	-0.7	0.98	-0.94	-0.63	0.76	0.98	0.79	-0.69
Short Long Term Debt Total	0.06		0.51	0.92	0.02	-0.21	-0.46	0.24	-0.67	0.23	-0.01	-0.71	0.3	0.94	0.23	0.97	-0.66	-0.22	-0.13	0.23	-0.22	-0.11	0.15	0.23	0.16	-0.12
Other Current Liab	0.57	0.51		0.79	0.53	-0.73	-0.97	0.72	-0.96	0.74	0.78	-0.8	0.91	0.76	0.75	0.36	-0.97	-0.59	-0.92	0.72	-0.59	-0.91	0.9	0.72	0.89	-0.91
Total Current Liabilities	0.28	0.92	0.79		0.23	-0.45	-0.75	0.47	-0.91	0.48	0.3	-0.89	0.63	0.99	0.48	0.84	-0.9	-0.43	-0.49	0.46	-0.43	-0.48	0.51	0.46	0.51	-0.49
Total Stockholder Equity	1.0	0.02	0.53	0.23		-0.97	-0.71	0.96	-0.41	0.96	0.78	-0.08	0.31	0.28	0.96	-0.2	-0.47	-0.93	-0.66	0.97	-0.93	-0.59	0.73	0.97	0.76	-0.65
Net Debt	-0.98	-0.21	-0.73	-0.45	-0.97		0.86	-1.0	0.63	-1.0	-0.85	0.31	-0.5	-0.49	-1.0	0.01	0.67	0.93	0.79	-1.0	0.93	0.73	-0.84	-1.0	-0.87	0.78
Retained Earnings	-0.75	-0.46	-0.97	-0.75	-0.71	0.86		-0.87	0.93	-0.88	-0.81	0.73	-0.84	-0.74	-0.88	-0.28	0.95	0.78	0.92	-0.86	0.78	0.9	-0.94	-0.86	-0.95	0.92
Cash	0.98	0.24	0.72	0.47	0.96	-1.0	-0.87		-0.64	1.0	0.82	-0.34	0.51	0.51	1.0	0.01	-0.69	-0.95	-0.78	1.0	-0.95	-0.72	0.84	1.0	0.87	-0.77
Non Current Assets Total	-0.46	-0.67	-0.96	-0.91	-0.41	0.63	0.93	-0.64		-0.66	-0.59	0.92	-0.89	-0.87	-0.66	-0.55	1.0	0.57	0.8	-0.63	0.57	0.8	-0.8	-0.63	-0.8	0.81
Cash And Short Term Investments	0.97	0.23	0.74	0.48	0.96	-1.0	-0.88	1.0	-0.66		0.83	-0.36	0.54	0.51	1.0	0.01	-0.7	-0.95	-0.8	1.0	-0.95	-0.75	0.86	1.0	0.88	-0.8
Common Stock Shares Outstanding	0.79	-0.01	0.78	0.3	0.78	-0.85	-0.81	0.82	-0.59	0.83		-0.26	0.65	0.3	0.83	-0.2	-0.63	-0.63	-0.92	0.82	-0.63	-0.86	0.88	0.82	0.88	-0.87
Non Current Liabilities Total	-0.14	-0.71	-0.8	-0.89	-0.08	0.31	0.73	-0.34	0.92	-0.36	-0.26		-0.84	-0.82	-0.37	-0.65	0.9	0.34	0.58	-0.33	0.34	0.63	-0.6	-0.33	-0.59	0.63
Other Current Assets	0.36	0.3	0.91	0.63	0.31	-0.5	-0.84	0.51	-0.89	0.54	0.65	-0.84		0.56	0.54	0.2	-0.88	-0.43	-0.89	0.5	-0.43	-0.93	0.87	0.5	0.85	-0.91
Total Liab	0.33	0.94	0.76	0.99	0.28	-0.49	-0.74	0.51	-0.87	0.51	0.3	-0.82	0.56		0.51	0.85	-0.87	-0.46	-0.45	0.5	-0.46	-0.43	0.47	0.5	0.48	-0.45
Total Current Assets	0.97	0.23	0.75	0.48	0.96	-1.0	-0.88	1.0	-0.66	1.0	0.83	-0.37	0.54	0.51		0.01	-0.71	-0.94	-0.81	1.0	-0.94	-0.75	0.86	1.0	0.89	-0.8
Short Term Debt	-0.17	0.97	0.36	0.84	-0.2	0.01	-0.28	0.01	-0.55	0.01	-0.2	-0.65	0.2	0.85	0.01		-0.52	0.0	0.05	0.0	0.0	0.05	-0.04	0.0	-0.04	0.05
Common Stock	-0.51	-0.66	-0.97	-0.9	-0.47	0.67	0.95	-0.69	1.0	-0.7	-0.63	0.9	-0.88	-0.87	-0.71	-0.52		0.61	0.82	-0.68	0.61	0.82	-0.83	-0.68	-0.83	0.83
Other Liab	-0.94	-0.22	-0.59	-0.43	-0.93	0.93	0.78	-0.95	0.57	-0.95	-0.63	0.34	-0.43	-0.46	-0.94	0.0	0.61		0.65	-0.95	1.0	0.62	-0.76	-0.95	-0.79	0.68
Net Tangible Assets	-0.7	-0.13	-0.92	-0.49	-0.66	0.79	0.92	-0.78	0.8	-0.8	-0.92	0.58	-0.89	-0.45	-0.81	0.05	0.82	0.65		-0.78	0.65	0.99	-0.99	-0.78	-0.98	0.99
Property Plant And Equipment Net	0.98	0.23	0.72	0.46	0.97	-1.0	-0.86	1.0	-0.63	1.0	0.82	-0.33	0.5	0.5	1.0	0.0	-0.68	-0.95	-0.78		-0.95	-0.71	0.84	1.0	0.86	-0.77
Warrants	-0.94	-0.22	-0.59	-0.43	-0.93	0.93	0.78	-0.95	0.57	-0.95	-0.63	0.34	-0.43	-0.46	-0.94	0.0	0.61	1.0	0.65	-0.95		0.62	-0.76	-0.95	-0.79	0.68
Accounts Payable	-0.63	-0.11	-0.91	-0.48	-0.59	0.73	0.9	-0.72	0.8	-0.75	-0.86	0.63	-0.93	-0.43	-0.75	0.05	0.82	0.62	0.99	-0.71	0.62		-0.98	-0.71	-0.97	1.0
Non Currrent Assets Other	0.76	0.15	0.9	0.51	0.73	-0.84	-0.94	0.84	-0.8	0.86	0.88	-0.6	0.87	0.47	0.86	-0.04	-0.83	-0.76	-0.99	0.84	-0.76	-0.98		0.84	1.0	-0.99
Net Receivables	0.98	0.23	0.72	0.46	0.97	-1.0	-0.86	1.0	-0.63	1.0	0.82	-0.33	0.5	0.5	1.0	0.0	-0.68	-0.95	-0.78	1.0	-0.95	-0.71	0.84		0.86	-0.77
Common Stock Total Equity	0.79	0.16	0.89	0.51	0.76	-0.87	-0.95	0.87	-0.8	0.88	0.88	-0.59	0.85	0.48	0.89	-0.04	-0.83	-0.79	-0.98	0.86	-0.79	-0.97	1.0	0.86		-0.99
Retained Earnings Total Equity	-0.69	-0.12	-0.91	-0.49	-0.65	0.78	0.92	-0.77	0.81	-0.8	-0.87	0.63	-0.91	-0.45	-0.8	0.05	0.83	0.68	0.99	-0.77	0.68	1.0	-0.99	-0.77	-0.99

Click cells to compare fundamentals

MoonLake Immunotherapeuti Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for MoonLake Stock Analysis

When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

MoonLake Net Income Per Share vs Free Cash Flow Yield Analysis

Net Income Per Share vs Free Cash Flow Yield

Net Income Per Share vs Free Cash Flow Yield Correlation Analysis

Correlation Coefficient

Net Income Per Share

Free Cash Flow Yield

MoonLake Immunotherapeuti fundamental ratios Correlations

MoonLake Immunotherapeuti Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for MoonLake Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Property Plant And Equipment Net	+ 1.0	Cash
Net Receivables	+ 1.0	Cash
Common Stock	+ 1.0	Non Current Assets Total

Net Receivables	- 1.0	Net Debt
Property Plant And Equipment Net	- 1.0	Net Debt
Total Current Assets	- 1.0	Net Debt
Cash And Short Term Investments	- 1.0	Net Debt
Cash	- 1.0	Net Debt
Retained Earnings Total Equity	- 0.99	Common Stock Total Equity